Watch ACRV. Know when insiders buy.
One email the day a filing lands. Free.
Work order
61
WATCH · insiders 48, shorts 74
Insiders, 90 days
−$35K
net selling · 0 buys, 3 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $91.3MP/E —DIV YIELD —FCF YIELD -70.27%REV TTM —NET INCOME −$74.2MNET CASH —52W 1.29 – 3.01SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$18.7M | −$18M | — | -0.43 | −$14.9M | $87K | −$14.9M | Aug 12 |
| Q1 2026 · Mar 31 | — | — | — | −$19.9M | −$19M | — | -0.49 | −$20.5M | $14K | −$20.6M | Aug 12 |
| Q4 2025 · Dec 31derived | — | — | — | −$20.1M | −$19M | — | -0.49 | −$15.2M | $219K | −$15.5M | Mar 19 |
| Q3 2025 · Sep 30 | — | — | — | −$19.7M | −$18.2M | — | -0.47 | −$12.3M | $899K | −$13.2M | Nov 13 |
| Q2 2025 · Jun 30 | — | — | — | −$22.6M | −$21M | — | -0.55 | −$16.6M | $493K | −$17.1M | Aug 12 |
| Q1 2025 · Mar 31 | — | — | — | −$21.7M | −$19.7M | — | -0.51 | −$19.5M | $58K | −$19.6M | Aug 12 |
| Q4 2024 · Dec 31derived | — | — | — | −$25M | −$22.8M | — | -0.59 | −$17.4M | $827K | −$18.2M | Mar 19 |
| Q3 2024 · Sep 30 | — | — | — | −$25.1M | −$22.4M | — | -0.59 | −$17.3M | $989K | −$18.3M | Nov 13 |
| Q2 2024 · Jun 30 | — | — | — | −$21.4M | −$18.8M | — | -0.52 | −$13.9M | $137K | −$14M | Nov 13 |
| Q1 2024 · Mar 31 | — | — | — | −$17.7M | −$16.5M | — | -0.73 | −$17.1M | $815K | −$17.9M | Nov 13 |
| Q4 2023 · Dec 31derived | — | — | — | −$21.1M | −$19.3M | — | -0.87 | −$12.4M | $1.2M | −$13.5M | Mar 27 |
| Q3 2023 · Sep 30 | — | — | — | −$16.1M | −$14.5M | — | -0.66 | −$9.8M | $0 | −$9.8M | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$84.1M | −$77.9M | — | -2.02 | −$63.7M | $1.7M | −$65.3M | — | — |
| FY2024 · to Dec 31 | — | — | −$89.2M | −$80.6M | — | -2.38 | −$65.7M | $2.8M | −$68.4M | — | — |
| FY2023 · to Dec 31 | — | — | −$67.1M | −$60.4M | — | -2.74 | −$42.6M | $1.3M | −$43.9M | — | — |
| FY2022 · to Dec 31 | — | — | −$32.7M | −$31.2M | — | -7.56 | −$30.1M | $2.2M | −$32.3M | — | — |
| FY2021 · to Dec 31 | — | — | −$16.2M | −$16.2M | — | -9.32 | −$14M | $238K | −$14.2M | — | — |
Every number comes from Acrivon Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.